Skip to main content

MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

  • RegistryNCT05836896
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNeoplasms
  • SponsorTechnische Universität Dresden
How CARLOTTA01 worksNCT058368961 min

What the film says

Read the transcript

Multiple myeloma comes back, again and again, until the standard drug classes are exhausted. CAR T cells aimed at BCMA, a marker on myeloma cells, are approved and effective, but relapses follow.

The idea: an academic BCMA CAR T, built with a tighter grip on its target.

At the University Hospital in Dresden, a patient's own T cells receive a high-affinity receptor for BCMA, designed to bind the marker more firmly than earlier constructs. After conditioning chemotherapy, the cells are returned in a single infusion, at one of four rising dose levels.

CARLOTTA-01 is a first safety study, for myeloma after at least two prior lines and for some relapsed large B-cell lymphomas. Martin Wermke leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05836896

    Myeloma relapses through drug classes (IMiD, PI, anti-CD38); High-affinity BCMA CAR; Conditioning chemotherapy then single IV infusion; four dose levels; Myeloma and relapsed/refractory DLBCL cohorts; Martin Wermke; Dresden

The drug

What is being tested.

Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy

The study

How the trial runs.

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Male or female patients aged ≥ 18 years
  • Written informed consent of the subject
  • Able and willing to adhere to the trial protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Either Multiple Myeloma (MM):
  • relapsed or refractory disease after at least 2 lines of treatment including an Immunomodulatory drug, a proteasome inhibitor and an anti-cluster of differentiation 38 antibody or anti-cluster of differentiation 319 (SLAMF7; Elotuzumab) antibody AND

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.